Page 158 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

114 MEDICAMENTS INDUISANTDES MODIFICATIONS COVALENTES DE L'ADN

ICHIKAWA T. et al., Intraneoplastic polymer-based delivery of cyclophosphamide for
intratumoral bioconversion by a replicating oncolytic viral vector, Cancer Res., 2001,
61, 864-868.
SREERAMA L., SLADEK N.E., Primary breast tumor level of suspected molecular deter-
minants of cellular sentivity to cyclophosphamide, ifosfamide and certain other anti-
cancer agents as predicators of paired metastatic tumor levais of these determinants,
Cancer Chemother. Pharmacol., 2001, 47, 255-262.

MODE D'ACTION
ENGLE T.W. et al., '?P NMR kinetic studies on the intra- and inter molecular alkylation
chemistry of phosphoramide mustard and cognate N-phosphorylated derivatives of
N, N-bis(2-chloroethyl)amine, J. Med. Chem., 1982, 41, 1347-1357.
SHULMAN-ROSKES E. et al., The partitioning of phosphoramide mustard and its aziri-
dinium ions among alkylation and P-N bond hydrolysis reactions, JI. Med. Chem.,
1998, 41, 515-529.
6
FRIEDMAN H.S. et al., Modulation of cyclophosphamide activity by 0 -alkylguanine-
DNA alkyltranferase, Cancer Chemother. Pharmacol., 1999, 43, 80-85.
FLOWERS J.L. et al., Evidence for a role of chloroethylaziridine in the cytotoxicity of
cyclophosphamide, Cancer Chemother. Pharmacol., 2000, 45, 335-344.

USAGES
REMICK S.C. et al., Oral combination chemotherapy in the management of AIDS-related
lyrnphoproliferative malignancies, Drugs, 1999, 58 (Supp. 3), 99-107.
AZIZ Z. et al., lfosfarnide and vinorelbine in rnetastatic breast cancer in patients with prier
anthracycline therapy, Cancer Chemother. Pharmacol., 1999, 44 (supp.), S9-S12.
DAVIDSON N.G.P. et al., FILM (5-fluorouracil, ifosfarnide, leucovorin and rnitornycine C)
an alternative chernotherapy regirnen suitable for the treatrnent of advenced breast
cancer in the « out-patient » setting, CancerChemother. Pharmacol., 1999, 44 (supp.),
S18-$23.
CHANG A.Y et al., lfosfarnide, carboplatin and etoposide (ICE) in rnetastatic and refrac-
tory breast cancer, Cancer Chemother. Pharmacol., 1999, 44 (supp.), S26-S28.
CAMPISIC. et al., lfosfarnide given by continuous infusion in association with vinorelbine
in patients with anthracycline-resistant metastatic breast cancer: a phase 1-11 clinical
trial, Cancer Chemother. Pharmacol., 1999, 44 (supp.), S1-S4.
LOBO F. et al., Phase Il study of ifosfarnide plus vinorelbine in rnetastatic breast cancer
patients previously treated with combination chernotherapy, Cancer Chemother.
Pharmacol., 1999, 44 (supp.), S5-S8.
GRUNBERG S.M. et al., Treatrnent of poor-prognosis extensive disease srnall-cell lung
cancer with an ail-oral regirnen of etoposide and cyclophosphamide - a Southwest
oncology Group clinical trial and pharmacokinetic study, CancerChemother. Pharma-
col., 1999, 44, 461-468.
SERRONE L. et al., A phase Il study of dose-intense ifosfarnide plus epirubicin with
hernatopoietic growth factors for the treatrnent of patients with advanced soft tissue
sarcornas ; a navel sequential schedule, Cancer Chemother. Pharmacol., 2001,
47,206-210.